Alex Kesin's Pharmacopoeia
Alex KesinRuminations about biotech and drug development - one overly earnest blog post at a time.
| Platform |  | Pricing | Freemium | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 34 | Subscribers | Read | alexkesin.com |
Curious about how many subscribers Alex Kesin's Pharmacopoeia has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over three million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Fun with FGF21
In September 2021, Bristol Myers Squibb discontinued development of pegbelfermin, a PEGylated version of a hormone called FGF21, after spending years and probably hundreds of millions of dollars testing it in patients with liver disease. Th...
How Amgen Lost The PCSK9 Patent War
Patent law rests on a simple covenant: inventors reveal their secrets, and society grants them temporary monopolies in return. But some companies want the monopoly without the showing. They want the treasure. They don’t want to draw the map...
The Cowboy Of Generic Drugs
The other customers at SuperPharm were beginning to stare.
The Day Novartis Chose Discovery
In 2002, Mark Fishman walked into a glass building in Cambridge with an unusual assignment: to turn the Swiss pharmaceutical company, Novartis, into the world’s greatest therapeutics research firm. More unusually still, Fishman was — at lea...
Similar Newsletters
Other publications recommended by the authors of this newsletter.
Authors
The writers behind this newsletter.
I write about drugs (the legal kind).
Frequently Asked Questions
How can I access the email archive for Alex Kesin's Pharmacopoeia?
You can find recent issues that have been published by Alex Kesin's Pharmacopoeia on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Alex Kesin's Pharmacopoeia have?
To see how many people subscribe to Alex Kesin's Pharmacopoeia, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Alex Kesin's Pharmacopoeia?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Alex Kesin's Pharmacopoeia as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Alex Kesin's Pharmacopoeia?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Alex Kesin's Pharmacopoeia using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to Alex Kesin's Pharmacopoeia?
Scroll up to where it says Similar Newsletters to see other publications like Alex Kesin's Pharmacopoeia. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Alex Kesin's Pharmacopoeia?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.